11 Analysts Have This to Say About Cytokinetics
Portfolio Pulse from Benzinga Insights
In the last 3 months, 11 analysts have provided 12-month price targets for Cytokinetics (NASDAQ:CYTK), with an average price target of $56.82, a 6.24% decrease from the previous average of $60.60. The ratings include 7 bullish, 4 somewhat bullish, and no bearish opinions.
June 20, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cytokinetics (NASDAQ:CYTK) has received 11 analyst ratings in the last 3 months, with an average 12-month price target of $56.82, down 6.24% from the previous average.
The average 12-month price target for Cytokinetics has decreased by 6.24% from the previous average, indicating a potential short-term neutral impact on the stock price. The majority of the analyst ratings are bullish or somewhat bullish, but the decrease in the average price target may cause some uncertainty among investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100